Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $25.00 | Outperform | Wolfe Research |
| 1/30/2026 | $30.00 | Buy | Jefferies |
Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00
Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00
The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%, representing more than 1 in 10 U.S. adults Definium Therapeutics, Inc. ("Definium" or the "Company"), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and growing burden affecting more than 1 in 10 adults in the U.S. Together, these resul
Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 55,580 common shares of the Company (the "Options") with effective grant dates of March 16, 2026 and March 30, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversar
Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definium's executive leadership team and external key opinion leaders who will provide clinical and real-world context on the evolving treatment landscape in generalized anxiety disorder (GAD) and major depressive disorder (MDD). Key areas of discussion will include DT120 ODT (lysergide tartrate), Defin
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
144 - Definium Therapeutics, Inc. (0001813814) (Subject)
10-K - Definium Therapeutics, Inc. (0001813814) (Filer)
8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder
Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation